Polycythemia vera differential diagnosis: Difference between revisions

Jump to navigation Jump to search
Line 109: Line 109:
|-
|-
! align="center" style="background:#DCDCDC;" |[[Chronic myeloid leukemia]] (CML)   
! align="center" style="background:#DCDCDC;" |[[Chronic myeloid leukemia]] (CML)   
|
| align="center" style="background:#F5F5F5;" |-
|
| align="center" style="background:#F5F5F5;" |-
|
| align="left" style="background:#F5F5F5;" |
* Reciprocal translocation of chromosomes 9 and 22
* Reciprocal translocation of chromosomes 9 and 22
* Production of BCR-Abl kinase
* Production of BCR-Abl kinase
| +
| align="center" style="background:#F5F5F5;" |+
| +
| align="center" style="background:#F5F5F5;" |+
| +
| align="center" style="background:#F5F5F5;" |+
|[[Abdominal pain]]
| align="center" style="background:#F5F5F5;" |[[Abdominal pain]]
|
| align="center" style="background:#F5F5F5;" |
|
| align="center" style="background:#F5F5F5;" |
| +
| align="center" style="background:#F5F5F5;" |+
|
| align="center" style="background:#F5F5F5;" |
| +
| align="center" style="background:#F5F5F5;" |+
|
| align="center" style="background:#F5F5F5;" |
|↑
| align="center" style="background:#F5F5F5;" |↑
|↑
| align="center" style="background:#F5F5F5;" |↑
|↑
| align="center" style="background:#F5F5F5;" |↑
|↑
| align="center" style="background:#F5F5F5;" |↑
|
| align="center" style="background:#F5F5F5;" |
|Elevated metamyelocytes and other [[white blood cells]] at various stages of maturation
| align="center" style="background:#F5F5F5;" |Elevated metamyelocytes and other [[white blood cells]] at various stages of maturation
|
| align="center" style="background:#F5F5F5;" |
|
| align="left" style="background:#F5F5F5;" |
* [[Imatinib]]
* [[Imatinib]]
* [[Dasatinib]]
* [[Dasatinib]]
Line 138: Line 138:
* [[Ponatinib]] for T315I kinase domain mutation
* [[Ponatinib]] for T315I kinase domain mutation
* [[Interferon-alpha]]
* [[Interferon-alpha]]
|
| align="left" style="background:#F5F5F5;" |
* Can appear similar to [[leukemoid reaction]]
* Can appear similar to [[leukemoid reaction]]
|-
|-
! align="center" style="background:#DCDCDC;" |[[Primary myelofibrosis]] (PMF)  
! align="center" style="background:#DCDCDC;" |[[Primary myelofibrosis]] (PMF)  
|
| align="center" style="background:#F5F5F5;" |
|
| align="center" style="background:#F5F5F5;" |
|
| align="left" style="background:#F5F5F5;" |
* Clonal disorder of [[megakaryocytes]]
* Clonal disorder of [[megakaryocytes]]
* Excess production [[TGF-beta]] and [[collagen]]
* Excess production [[TGF-beta]] and [[collagen]]
| +
| align="center" style="background:#F5F5F5;" | +
|
| align="center" style="background:#F5F5F5;" |
| +
| align="center" style="background:#F5F5F5;" | +
|[[Abdominal pain]]
| align="center" style="background:#F5F5F5;" |[[Abdominal pain]]
|
| align="left" style="background:#F5F5F5;" |
* Early satiety
* Early satiety
|Pallor
| align="center" style="background:#F5F5F5;" |Pallor
|
| align="center" style="background:#F5F5F5;" |
|
| align="center" style="background:#F5F5F5;" |
| +
| align="center" style="background:#F5F5F5;" | +
|
| align="left" style="background:#F5F5F5;" |
* [[Hepatomegaly]]
* [[Hepatomegaly]]
* [[Bruising]]
* [[Bruising]]
|↓
| align="center" style="background:#F5F5F5;" |↓
|↓
| align="center" style="background:#F5F5F5;" |↓
|↓
| align="center" style="background:#F5F5F5;" |↓
|↓
| align="center" style="background:#F5F5F5;" |↓
|
| align="center" style="background:#F5F5F5;" |
|
| align="center" style="background:#F5F5F5;" |
|
| align="center" style="background:#F5F5F5;" |
|
| align="left" style="background:#F5F5F5;" |
* [[Hydroxyurea]]
* [[Hydroxyurea]]
* [[Stem cell transplant]]
* [[Stem cell transplant]]
* [[Ruxolitinib]]
* [[Ruxolitinib]]
|
| align="left" style="background:#F5F5F5;" |
* Variable risk for development of [[acute leukemia]]
* Variable risk for development of [[acute leukemia]]
|-
|-
! align="center" style="background:#DCDCDC;" |Secondary polycythemia   
! align="center" style="background:#DCDCDC;" |Secondary polycythemia   
| -
| align="center" style="background:#F5F5F5;" |-
| -
| align="center" style="background:#F5F5F5;" |-
|
| align="left" style="background:#F5F5F5;" |
* [[Congestive heart failure]] (CHF)
* [[Congestive heart failure]] (CHF)
* [[Interstitial lung disease]] (ILD)
* [[Interstitial lung disease]] (ILD)
Line 183: Line 183:
* Chronic [[hypoxia]]  
* Chronic [[hypoxia]]  
* Ectopic [[erythropoietin]] production from tumor (renal cell carcinoma or hepatocellular carcinoma)
* Ectopic [[erythropoietin]] production from tumor (renal cell carcinoma or hepatocellular carcinoma)
| +
| align="center" style="background:#F5F5F5;" |+
| +
| align="center" style="background:#F5F5F5;" |+
| -
| align="center" style="background:#F5F5F5;" | -
|Depends on etiology
| align="center" style="background:#F5F5F5;" |Depends on etiology
|
| align="left" style="background:#F5F5F5;" |
* [[Shortness of breath]]
* [[Shortness of breath]]
|[[Cyanosis]]
| align="center" style="background:#F5F5F5;" |[[Cyanosis]]
|
| align="center" style="background:#F5F5F5;" |
|
| align="center" style="background:#F5F5F5;" |
|
| align="center" style="background:#F5F5F5;" |
|
| align="left" style="background:#F5F5F5;" |
* [[Crackles]]
* [[Crackles]]
* [[Tachypnea]]
* [[Tachypnea]]
* [[Tachycardia]]
* [[Tachycardia]]
|↑
| align="center" style="background:#F5F5F5;" |↑
|
| align="center" style="background:#F5F5F5;" |
|
| align="center" style="background:#F5F5F5;" |
|
| align="center" style="background:#F5F5F5;" |
|↑
| align="center" style="background:#F5F5F5;" |↑
|
| align="center" style="background:#F5F5F5;" |
|
| align="center" style="background:#F5F5F5;" |
|
| align="left" style="background:#F5F5F5;" |
* Treatment of underlying cause of [[hypoxia]]
* Treatment of underlying cause of [[hypoxia]]
* Supplemental oxygen
* Supplemental oxygen
Line 212: Line 212:
* [[Smoking cessation]] or nicotine replacement
* [[Smoking cessation]] or nicotine replacement
* Surgical removal of tumors
* Surgical removal of tumors
|
| align="left" style="background:#F5F5F5;" |
* Variable manifestations given the diverse etiologies
* Variable manifestations given the diverse etiologies
|-
|-

Revision as of 17:35, 20 August 2018

Polycythemia vera Microchapters

Home

Patient Information

Overview

Historical perspective

Classification

Pathophysiology

Causes

Differentiating Polycythemia vera from other Diseases

Epidemiology and Demographics

Risk Factors

Screening

Natural history, Complications and Prognosis

Diagnosis

Diagnostic Criteria

History and Symptoms

Physical Examination

Laboratory Findings

Electrocardiogram

X-ray

CT

MRI

Ultrasound

Other Imaging Findings

Other Diagnostic Studies

Treatment

Medical Therapy

Surgery

Primary Prevention

Secondary Prevention

Cost-Effectiveness of Therapy

Future or Investigational Therapies

Case Studies

Case #1

Polycythemia vera differential diagnosis On the Web

Most recent articles

Most cited articles

Review articles

CME Programs

Powerpoint slides

Images

American Roentgen Ray Society Images of Polycythemia vera differential diagnosis

All Images
X-rays
Echo & Ultrasound
CT Images
MRI

Ongoing Trials at Clinical Trials.gov

US National Guidelines Clearinghouse

NICE Guidance

FDA on Polycythemia vera differential diagnosis

CDC on Polycythemia vera differential diagnosis

Polycythemia vera differential diagnosis in the news

Blogs on Polycythemia vera differential diagnosis

Directions to Hospitals Treating Polycythemia vera

Risk calculators and risk factors for Polycythemia vera differential diagnosis

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1] Associate Editor(s)-in-Chief: Mohamad Alkateb, MBBCh [2]; Shyam Patel [3]

Overview

Polycythemia vera must be differentiated from other myeloproliferative neoplasms, such as chronic myelogenous leukemia, essential thrombocythemia, and primary myelofibrosis. Polycythemia vera must also be differentiated from secondary polycythemia, which is usually due to chronic hypoxia. Each of these conditions have different etiologies, symptoms, laboratory abnormalities, physical exam findings, and treatments.

Differential Diagnosis

Polycythemia vera must be differentiated from a variety of other conditions.[1][2][3]

Disease Mutation Etiology Symptoms Signs laboratory data Treatment Associated findings
CBC Erythropoietin level PBS PT/PTT
JAK2 mutation CALR mutation Fatigue Headache Bleeding Pain Other symptoms Appearance Fever Tenderness Splenomegaly Other signs Hb RBC WBC Plt
Polycythemia vera (PV) > 95% Autonomous erythrocyte production + - Ruddy face - - + NA ↑ RBC mass Nl to ↑ Nl to ↑
Essential thrombocythemia (ET) 50% +/-
  • Clonal proliferation of megakaryocytes
  • Excess platelet production
+ + (paradoxical)
  • Stroke-like symptoms
+ Bruises ↑ (dysfunctional platelets)
Chronic myeloid leukemia (CML) - -
  • Reciprocal translocation of chromosomes 9 and 22
  • Production of BCR-Abl kinase
+ + + Abdominal pain + + Elevated metamyelocytes and other white blood cells at various stages of maturation
Primary myelofibrosis (PMF) + + Abdominal pain
  • Early satiety
Pallor +
Secondary polycythemia - - + + - Depends on etiology Cyanosis
  • Treatment of underlying cause of hypoxia
  • Supplemental oxygen
  • Diuresis for CHF
  • Steroids for ILD
  • Continuous positive airway pressure for OSA
  • Smoking cessation or nicotine replacement
  • Surgical removal of tumors
  • Variable manifestations given the diverse etiologies

References

  1. Tefferi A, Barbui T (2015). "Polycythemia vera and essential thrombocythemia: 2015 update on diagnosis, risk-stratification and management". Am J Hematol. 90 (2): 162–73. doi:10.1002/ajh.23895. PMID 25611051.
  2. Sanchez S, Ewton A (2006). "Essential thrombocythemia: a review of diagnostic and pathologic features". Arch Pathol Lab Med. 130 (8): 1144–50. doi:10.1043/1543-2165(2006)130[1144:ET]2.0.CO;2. PMID 16879015.
  3. Jabbour E, Kantarjian H (2014). "Chronic myeloid leukemia: 2014 update on diagnosis, monitoring, and management". Am J Hematol. 89 (5): 547–56. doi:10.1002/ajh.23691. PMID 24729196.